Product Information
RANOLAZINE ER 500 MG TABLET is a generic product labeled by i3 Pharmaceuticals, LLC, priced at $0.1649 per EA under NDC 72319002102. Its NADAC has been published 201 times since Nov 30, 2022.
FDA first approved this application on Apr 27, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
i3 Pharmaceuticals, LLCNDC
72319002102
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RANOLAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA213517FDA Approved
4/27/2022
TE Code
AB
On Market Since
6/15/2022
Pharmacological Classes
Price Statistics
The NADAC for RANOLAZINE ER 500 MG TABLET has been published 201 times since Nov 30, 2022, and over the history we have for it it has declined 34.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1649 per EA |
|---|---|
| All-time high | $0.2647 (Jan 10, 2024) |
| All-time low | $0.1581 (Jul 22, 2026) |
| 52-week high | $0.1691 |
| 52-week low | $0.1581 |
| Median price | $0.2088 |
| Average price | $0.2040 |
| Largest weekly change | +17.6% (Aug 21, 2024) |
| Weeks tracked | 201 |
| Tracking since | Nov 30, 2022 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
i3 Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
RANOLAZINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-anginal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RANOLAZINE ER 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RANOLAZINE ER 500 MG TABLET, manufactured by i3 Pharmaceuticals, LLC, is $0.1649 per EA (NDC 72319002102), effective Sep 30, 2026.
How has the price of RANOLAZINE ER 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for RANOLAZINE ER 500 MG TABLET has declined 34.8%. It has been tracked across 201 weekly CMS publications since Nov 30, 2022.
What are the highest and lowest recorded NADAC prices for RANOLAZINE ER 500 MG TABLET?
Since Nov 30, 2022, the NADAC for RANOLAZINE ER 500 MG TABLET has ranged from a low of $0.1581 (Jul 22, 2026) to a high of $0.2647 (Jan 10, 2024), with a median of $0.2088 per EA.
Are there cheaper alternatives to RANOLAZINE ER 500 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RANOLAZINE ER 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RANOLAZINE ER 500 MG TABLET?
RANOLAZINE ER 500 MG TABLET (NDC 72319002102) is labeled by i3 Pharmaceuticals, LLC, and CMS classifies it as a generic product.